Single-Cell-Derived Tumor Organoid (STO) arrays on a microfluidic chip for personalized drug screening to address heterogeneity-induced drug resistance in colorectal cancer

Tumor heterogeneity drives chemotherapy resistance in cancer, necessitating the development of strategies to target diverse cellular subpopulations. Single-cell-derived tumor organoids (STOs), derived from individual tumor stem cells (TSCs), retain well-defined genomic and phenotypic attributes, making them instrumental in elucidating unique diversification. Here, we developed a microfluidic approach that utilizes STO arrays for personalized drug screening, aimed at overcoming heterogeneity induced drug resistance in colorectal cancer. We utilized a microwell array format microfluidic chip to the generation of a high scale STO array. This array encompasses two key features: (1) STOs in individual microwells are derived from single TSCs, which allows for a high-resolution display of cellular heterogeneity; (2) it exhibits thousands of STOs at predefined locations on the same focal plane, thereby facilitating automated, high-content analyses using imaging data. Utilizing the STO array, we assess the responses of various subpopulations of colorectal cancer to a conventional chemotherapeutic regimen, facilitating the phenotypic identification of resistant STOs. Through the analysis of RNA sequencing data from the resistant STOs, candidate drugs targeting resistance-associated pathways were identified for individual patients. Furthermore, the candidate drugs were validated through STO-array drug testing, demonstrating enhanced clearance effects when combined with the conventional regimen. Our study establishes a scalable, patient-specific drug screening approach that integrates phenotypic and molecular analyses, offering a transformative strategy to overcome heterogeneity-driven drug resistance in colorectal cancer. The microfluidic platform presented herein holds significant potential for advancing precision oncology and personalized therapeutic design.

Authors

Institutions

Publication Details

Journal
Microsystems & Nanoengineering
Published
2025-12-22
DOI
https://doi.org/10.1038/s41378-025-01068-1
Citations
1
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
1.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Single-Cell-Derived Tumor Organoid (STO) arrays on a microfluidic chip for personalized drug screening to address heterogeneity-induced drug resistance in colorectal cancer

X. Wang, D Liu, Jueming Chen, Yanzhang Luo et al.
1 citations
Microsystems & Nanoengineering
Cancer Cells and Metastasis
1.05
article

Single-Cell-Derived Tumor Organoid (STO) arrays on a microfluidic chip for personalized drug screening to address heterogeneity-induced drug resistance in colorectal cancer

X. Wang, D Liu, Jueming Chen, Yanzhang Luo, Ziqing Ma, Dongguo Lin, Hui Kang, Lihui Wang
article en
1 citations

Abstract

Tumor heterogeneity drives chemotherapy resistance in cancer, necessitating the development of strategies to target diverse cellular subpopulations. Single-cell-derived tumor organoids (STOs), derived from individual tumor stem cells (TSCs), retain well-defined genomic and phenotypic attributes, making them instrumental in elucidating unique diversification. Here, we developed a microfluidic approach that utilizes STO arrays for personalized drug screening, aimed at overcoming heterogeneity induced drug resistance in colorectal cancer. We utilized a microwell array format microfluidic chip to the generation of a high scale STO array. This array encompasses two key features: (1) STOs in individual microwells are derived from single TSCs, which allows for a high-resolution display of cellular heterogeneity; (2) it exhibits thousands of STOs at predefined locations on the same focal plane, thereby facilitating automated, high-content analyses using imaging data. Utilizing the STO array, we assess the responses of various subpopulations of colorectal cancer to a conventional chemotherapeutic regimen, facilitating the phenotypic identification of resistant STOs. Through the analysis of RNA sequencing data from the resistant STOs, candidate drugs targeting resistance-associated pathways were identified for individual patients. Furthermore, the candidate drugs were validated through STO-array drug testing, demonstrating enhanced clearance effects when combined with the conventional regimen. Our study establishes a scalable, patient-specific drug screening approach that integrates phenotypic and molecular analyses, offering a transformative strategy to overcome heterogeneity-driven drug resistance in colorectal cancer. The microfluidic platform presented herein holds significant potential for advancing precision oncology and personalized therapeutic design.

Microsystems & NanoengineeringVol. 11(1)
Jinan University (CN), Guangzhou First People's Hospital (CN), South China University of Technology (CN), Guangzhou Medical University (CN)
National Natural Science Foundation of China, Guangdong Science and Technology Department, Guangzhou First People's Hospital
Good health and well-being
Openalex Percentile: Top 15%
Cancer Cells and Metastasis
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.